Clinical trials: Age 65 and Older
Influenza
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
The primary objective of the study was to provide sera (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to the Center for Biologics Evaluation and Research (CBER) for…
- Trial name
- GRC00097 (NCT04109222)
- Testing
- Fluzone Quadrivalent vaccine, no preservative (0.5-mL), 2019-2020 formulation, Fluzone High-Dose vaccine, 2019-2020 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7)
Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
This phase II trial studies the side effects and how well omacetaxine mepesuccinate, cytarabine, and decitabine work in treating older patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a)
- Trial name
- NCT02029417
- Testing
- cytarabine, omacetaxine mepesuccinate, decitabine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Roswell Park Cancer Institute
Influenza, Human
A Study to Assess the Safety and Immune Response of Quadrivalent Seasonal Influenza Vaccine (Fluarix Tetra) in Participants Aged 65 Years and Older in India
The purpose of this study is to gather additional evidence of the safety and immunogenicity of 1 dose of Fluarix Tetra (0.5 milliliter [mL]) (Northern Hemisphere (NH)2023-2024) in individuals aged 65 years and above to fulfill a…
- Trial name
- NCT05648357
- Testing
- Fluarix Tetra Vaccine
- Where
- 6 sites in India
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
A Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine GSK3206641A Administered in Adults 18 to 64 Years of Age and 65 Years of Age and Older
Study to evaluate the safety and immunogenicity of H7N9 antigen in combination with full or half doses of AS03 adjuvant system in healthy adults.
- Trial name
- NCT04789577
- Testing
- FLU-Q-PAN H7N9 Formulation 1, FLU-Q-PAN H7N9 Formulation 2, FLU-Q-PAN H7N9 Formulation 3
- Where
- 8 sites in United States
- Volunteers
- 833 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acute Myeloid Leukemia
Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
The purpose of this study is to determine the safety and effectiveness of pracinostat when combined with azacitadine for patients who are 65 years of age or older and have Acute Myelogenous Leukemia (AML)
- Trial name
- NCT01912274
- Testing
- Pracinostat, Azacitidine
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Helsinn Healthcare SA
Respiratory Syncytial Virus
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age
The purpose of this study is to assess the safety and immunogenicity of RSVpreF when coadministered with SIIV compared to sequential administration of the vaccines when given 1 month apart (SIIV followed by RSVpreF).
- Trial name
- NCT05301322
- Testing
- RSVpreF Vaccine, Seasonal Inactivated Influenza Vaccine
- Where
- 33 sites in Australia
- Volunteers
- 1,471 people, healthy volunteers welcome
- Sponsor
- Pfizer
Kidney Transplant; Complications, Toxicity
Effect of Tacrolimus Formulation on Neurological Side Effects in Older Kidney Transplant Recipients
Previous studies have shown that elderly patients experience higher trough levels of tacrolimus and are more sensitive to the effects of medications, they experience higher occurrence and severity of such medication related…
- Conditions
- Kidney Transplant; Complications, Toxicity, Drug Toxicity, Neurotoxicity
- Trial name
- NCT03461445
- Testing
- Envarsus, IR Tacrolimus
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, Davis
Tetanus, Acellular Pertussis
Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine.
This phase IIIb, observer-blind study will evaluate the immunogenicity and safety of GSK Biologicals' Boostrix® vaccine in adults (extending indication) aged 65 years or older.
- Conditions
- Tetanus, Acellular Pertussis, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
- Trial name
- NCT00835237
- Testing
- Boostrix®, Decavac™
- Where
- 24 sites in United States
- Volunteers
- 1,332 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human Prevention, Respiratory Syncytial Viruses Prevention
A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older
The purpose of this study is to evaluate the immunogenicity and safety of Ad26.RSV.preF-based vaccine and quadrivalent high-dose seasonal influenza vaccine when administered either concomitantly or separately.
- Trial name
- NCT05071313
- Testing
- Ad26.RSV.preF-based vaccine, Quadrivalent High-dose Influenza Vaccine
- Where
- 19 sites in United States
- Volunteers
- 777 people
- Sponsor
- Janssen Vaccines & Prevention B.V.
Influenza
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Patients ≥65 Years
This phase I/II, randomized, modified double-blind, multi-center study assessed the safety and immunogenicity of a high-dose Quadrivalent influenza vaccine (QIV-HD) in older adults (greater than or equal to [>=] 65 years).
- Trial name
- NCT03233217
- Testing
- QIV-HD by IM, QIV-SD by SC, QIV-HD by SC
- Where
- 2 sites in Japan
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza Immunization, Healthy Volunteers
Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively
Primary Objective: To provide serum samples (collected from participants before vaccination [Blood Sample 1] and after final vaccination [Blood Sample 2]) to Center for Biologics Evaluation and Research (CBER) for further…
- Trial name
- NCT04551677
- Testing
- Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2020-2021 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2020-2021 formulation
- Where
- 2 sites in United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Adjuvanted Seasonal Recombinant Quadrivalent Virus-Like Particles (QVLP) Influenza Vaccine in Adults 65 Years of Age and Older
This randomized, partially-blinded, active comparator-controlled was conducted at multiple sites globally. The composition of QVLP used in this study includes a mix of recombinant H1, H3, and two B hemagglutinin proteins…
- Trial name
- NCT04622592
- Testing
- Instramuscular vaccine
- Where
- 14 sites in United States
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Medicago
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
This phase III trial compares adding a new anti-cancer drug (venetoclax) to the usual treatment (ibrutinib plus obinutuzumab) in older patients with chronic lymphocytic leukemia who have not received previous treatment.
- Trial name
- NCT03737981
- Testing
- Ibrutinib, Obinutuzumab, Observation Activity
- Where
- 857 sites in United States
- Volunteers
- 465 people
- Sponsor
- National Cancer Institute (NCI)
Virus Diseases, RNA Virus Infections
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
This Phase 3 study was intended to assess the relative efficacy of the Quadrivalent VLP Influenza Vaccine during the 2018-2019 influenza season compared to a licensed vaccine in elderly adults 65 years of age and older.
- Conditions
- Virus Diseases, RNA Virus Infections, Respiratory Tract Diseases, Respiratory Tract Infections
- Trial name
- NCT03739112
- Testing
- Quadrivalent VLP Vaccine, Fluarix Quadrivalent® Comparator Vaccine
- Where
- 104 sites in United States, Canada and 3 more
- Volunteers
- 12,794 people, healthy volunteers welcome
- Sponsor
- Medicago
Multiple Myeloma
UARK 2003-25: A Study of Intravenous (IV) Busulfan (Busulfex®) in Multiple Myeloma Patients
The purpose of this study is to find out if patients with high risk disease because of age or kidney status can be treated more safely with a drug called Busulfex® followed by autologous transplant compared to treatment with the…
- Trial name
- NCT00113919
- Testing
- Busulfan
- Where
- 2 sites in United States
- Volunteers
- 14 people
- Sponsor
- University of Arkansas
Hypercholesterolemia
Ezetimibe and Atorvastatin vs. Atorvastatin in Patients Age 65 and Older at High Risk for Coronary Heart Disease (CHD)(0653-112)
A 12 week clinical trial in patients 65 years of age and older with hypercholesterolemia at high risk for coronary heart disease to study the effects of atorvastatin and ezetimibe given in combination and two higher doses of…
- Trial name
- NCT00418834
- Testing
- ezetimibe and atorvastatin, atorvastatin
- Volunteers
- 1,053 people
- Sponsor
- Organon and Co
Influenza (Healthy Volunteers)
Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older
Primary Objective: Immunogenicity: To describe the immune response induced by high-dose quadrivalent influenza vaccine (QIV-HD) and AdimFlu-S (QIS) by hemagglutinin inhibition (HAI) measurement method in all participants.
- Trial name
- NCT04537234
- Testing
- High-Dose Quadrivalent Influenza Vaccine, Standard-Dose Quadrivalent Influenza Vaccine
- Where
- 4 sites in Taiwan
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of 23-valent pneumococcal polysaccharide vaccine in…
- Trial name
- NCT01646398
- Testing
- 13-valent pneumococcal conjugate vaccine, 23-valent pneumococcal polysaccharide vaccine
- Where
- 8 sites in Japan
- Volunteers
- 764 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pneumococcal Disease, COVID-19
Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
- Conditions
- Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection
- Trial name
- NCT04887948
- Testing
- 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, Saline
- Where
- 27 sites in United States
- Volunteers
- 570 people, healthy volunteers welcome
- Sponsor
- Pfizer
Peripheral Arterial Disease
Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD)
This study is evaluating whether a therapeutic ultrasound device can improve symptoms in the leg of peripheral arterial disease (PAD) patients 65 years of age and over.
- Trial name
- Waltz (NCT05888740)
- Testing
- VibratoSleeve Therapeutic Ultrasound Device
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Vibrato Medical, Inc.